THE WOODLANDS, Texas--Genometrix, a maker of high-throughput microarray technology for applied genomics, diagnostic, and pharmaceutical development, announced it will sign an agreement with gene therapy products developer GeneMedicine to facilitate accelerated multiplex screening of biological responses in mouse tumor models. The collaboration will utilize Genometrix's medium-density DNA microarrays for high-throughput analysis of gene expression profiles in mice. Genometrix's Chief Scientific Officer Michael Hogan said Genometrix has developed proprietary technology for high-throughput, low-cost analysis of gene expression profiles. "During the past 24 months, special emphasis has been placed on the development of that technology for pharmaceutical development," Hogan said. "The new collaboration with GeneMedicine is timely because it allows Genometrix the opportunity to enter an important segment of the pharmaceutical development arena."
Genometrix Signs High-Throughput Screening Deal with GeneMedicine
Dec 18, 1998